First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study

Paredes, M.B.; González, F. del Moral; Prado, Purificación Martínez del; Ciriquián, J.L. Martí; Francés, Santos Enrech; Dols, M. Cobo; Esteban, Emilio; Granados, A.L. Ortega; Tarruella, M. Majem; Buron, Jose David Cumplido; Hernández, Andrés; Miranda, Elena; Santos, Jorge Pinheiro; Carpeño, F.J. de Castro

doi:10.1093/annonc/mdq449

Cited by 79 publications

(53 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar conclusions were drawn by Nunez while evaluating relatively critically the effectiveness of fentanyl in the treatment of neuropathic pain in the course of cancerous disease, and emphasizing that, in this indication, oxycodone may be considered as the first-line drug [29]. This is also confirmed by the studies by García de Paredes et al presenting the observations of a large group of patients treated with opioids in the same indication [35]. However, due to the fact that this is an observation study, it cannot be considered on the level of evidence-based medicine.…”

Section: Selection Of Opioidsupporting

confidence: 72%

Opioids in the treatment of chemotherapy-induced polyneuropathy

Brzeziński¹,

Chwedorowicz²

2011

View full text Add to dashboard Cite

Section: Selection Of Opioidsupporting

confidence: 72%

Opioids in the treatment of chemotherapy-induced polyneuropathy

Brzeziński¹,

Chwedorowicz²

2011

View full text Add to dashboard Cite

“…Pain decrease at 1 month was greater in patients with metastases. 56 The overall incidence of chemotherapy-induced peripheral neuropathy (CIPN) and of associated NP is high (30% to 70%). 23,57 Radiation can present with numerous clinical painful manifestations, ranging between 25 and 47%.…”

Section: 55mentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

“…The pain experienced by cancer patients is usually mixed, with nociceptive and neuropathic components. Among patients with neuropathic cancer pain, 69% of them experienced tumor-related pain and <43% experienced treatment-related pain (2). In the treatment-related pain patients, 79% of cases were due to chemotherapy or biological therapy.…”

Section: Introductionmentioning

confidence: 99%

Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy

et al. 2016

View full text Add to dashboard Cite

First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study

Abstract: NP prevalence in cancer pain is 33%. DN4 reports only about half the cancer NP cases diagnosed by clinicians. Pharmaceutical treatment of cancer pain, including NP, has a greater effect in patients with metastases and seems to depend on the specific treatment used.

Cited by 79 publications

References 25 publications

Opioids in the treatment of chemotherapy-induced polyneuropathy

Opioids in the treatment of chemotherapy-induced polyneuropathy

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy

Contact Info

Product

Resources

About